<DOC>
	<DOCNO>NCT03105232</DOCNO>
	<brief_summary>Side effect opioids practical view divide short-term long-term . Nervous system disorder manifest psychological status change patient may cause confusion , mental somatic dependency , dizziness . Influencing vegetative cardiovascular system hypotension occur manifestation vasodilation decrease myocardial inotropic activity . Another clinical sign bradycardia characterize general weakness , sweat , collapse develop . Effects opioids may cause respiratory depression , bronchospasm bronchoconstriction . Side effect gastrointestinal tract nausea , vomit , constipation less frequently dry mouth . The constipation develop tolerance avoid ( dietary modification , laxatives prevention ) respectively long-term opioid treatment obstipation affect block peripheral opioid receptor gastrointestinal tract application opioid antagonist methylnaltrexone , cross blood brain barrier , use naloxone , metabolize `` first-pass '' metabolism liver example combined preparation contain oxycodone naloxone ( Kulichov치 , 2012 ) . Known side effect parenchymatous organ especially liver restrict biliary excretion cause spasm biliary tract . Skin manifestation cause effect opioids urticaria , dermatitis , pruritus . Renal urinary disorder may develop urinary retention ureteral spasm . Rarely occur disorder immune system , development hypersensitivity may lead development anaphylactic shock ( Kulichov치 , 2012 ) . Opioids negative effect endocrine system . Various study demonstrate influence opioids regulatory mechanism . Fundamental change occur hypothalamic-pituitary complex , direct activity endocrine system . Secretion hormones pituitary gland regulate nervous system hypothalamus , coordination center autonomic function . The pituitary gland coordinate function relation endocrine gland , production hormone affect peripheral endocrine organ target tissue ( Kulichov치 , 2012 ) , ( Colameco , 2009 ) . Opioids decrease secretion gonadotropin-stimulating hormone , result reduce level luteinizing hormone . The result change reduce secretion testosterone estradiol result symptoms hypogonadism . Chronic administration exogenous opioids decrease level adrenocorticotropic hormone cortisol , well circadian rhythm . The result reduction response stress . Effect prolactin entirely clear . Opioids stimulate hypothalamus thyroid stimulate hormone , may cause prolong increase response opioids patient hypothyroidism . Chronic use opioids associate weight gain , hyperglycemia diabetes worsen ( Kulichov치 , 2012 ) . It may relate central effect sympathetic nervous system impaired insulin secretion . New laboratory measurement show development oxidative stress patient receive morphine relate drug ( Merdin , 2016 ) . The consequence biochemical change negatively affect clinical outcome patient . They may become predisposed excessive progression previously latent disease whose manifestation patient previously apparent emergence new disease . The present data essential create clinical prospective observational study clarify issue conclusion would essential new therapeutic option adjuvant therapy patient suffer chronic pain .</brief_summary>
	<brief_title>Opioid-Redox Study</brief_title>
	<detailed_description>The process study , choice patient , collection processing data A . Potential participant study familiarized course research every detail enter study signing inform consent examine algesiologist . The patient receive ID number generate computer preserve anonymity purpose statistical processing data . Monitored clinical parameter : The current consumption analgesic , examination type pain ( nociceptive vs. neuropathic - complete questionnaire PainDetect , DN4 LANSS Pain scale ) , demographic information ( weight , height , age ) . Examination biochemical parameter ( ALT , AST , GMT , bilirubin , urea , creatinine , creatinine clearance , antioxidant enzyme substrate ( glutathione peroxidase , glutathione reductase , catalase , superoxide dismutase , glutathione ) . These data enter online database . The statistical analysis activity enzymes determine confidence interval ( CI ) 95 % . Patients whose entrance number range keep study , remain patient exclude . The patient keep study divide four group . Group A : patient chronic pain take morphine , hydromorphone , oxycodone Group B : patient chronic pain take transdermal patch ( Buprenorphine ) Group C : patient chronic pain take transdermal patch ( Fentanyl ) Group D : opioid rotation B . The first inspection carry 6 month begin take opioids severe pain . During first inspection , clinical biochemical parameter examine input examination patient . The patient fill questionnaire PainDetect , DN4 LANSS Pain scale . C. The second inspection carry 12 month begin take opioids severe pain . During second inspection , clinical biochemical parameter examine previous two patient examination . The patient fill questionnaire PainDetect , DN4 LANSS Pain scale .</detailed_description>
	<mesh_term>Analgesics , Opioid</mesh_term>
	<criteria>opiod therapy active chemotherapy radiotherapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>